Serve patients and mitigate regulatory risk for manufacturers with a free drug program through a non-commercial pharmacy
Drug manufacturers often work with providers to cover the cost of life-saving drug therapies for patients in need. This goodwill gesture is admirable, but it can also subject the manufacturer to significant regulatory risks, including fines, sanctions and penalties for anti-kickback and inducement violations.
Sonexus™ Access & Patient Support services from Cardinal Health Specialty Solutions, offers manufacturers a free drug program that distributes the drugs through a non-commercial pharmacy. This model has been publicly supported by the Office of Inspector General (OIG) of the Department of Health and Human Services. By using a non-commercial pharmacy, our model mitigates risk and further reduces the opportunity for actual or perceived inducement.
In this informative whitepaper, you’ll learn:
- The inherent risks associated with free drug programs
- How non-commercial pharmacies add a deeper layer of protection that guards against actual and perceived inducement
- OIG-recognized benefits of free drug programs
- How free drug programs help commercially and government insured patients, as well as uninsured patients